Physician profile
Jennifer L Mondillo
NPI 1366737660
$396,323.84
in general payments reported to CMS, 2019-2025
10 companies · $172K in 2025
The $172K reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $350 · 2022: $458 · 2023: $112K · 2024: $111K · 2025: $172K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $286K · Travel and Lodging: $57K · Consulting Fee: $42K · Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $285,885.00 |
| Travel and Lodging | $56,904.08 |
| Consulting Fee | $42,015.49 |
| Food and Beverage | $10,710.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $378,044.89 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $16,348.87 | 2022-2025 | Rexulti |
| Acadia Pharmaceuticals INC | $1,214.74 | 2022-2025 | Nuplazid |
| E.R. Squibb & Sons, L.L.C. | $386.94 | 2023-2025 | Eliquis |
| Urovant Sciences INC | $118.50 | 2021 | |
| Amgen INC. | $91.20 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $55.10 | 2025 | Rexulti |
| Sumitomo Pharma America, INC. | $38.10 | 2023 | Gemtesa |
| Ermi LLC | $12.86 | 2021 | |
| Alpha Cognition USA, INC. | $12.64 | 2025 | Zunveyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Mondillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.